Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 779-801

  Santoni, Matteo ^a   Paccapelo, Alessandro ^a   Burattini, Luciano ^a   Bianconi, Maristella ^a   Cardinali, Massimo ^a   Fabbietti, Letizia ^a   Trignani, Roberto ^a   Rychlicki, Franco ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Clinical trials; Glioblastoma; Low dose temozolomide; Overall survival; Progression free survival

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TUMOR RECURRENCE;

EID: 84864723469     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.788     Document Type: Article

References (10)

1. Reardon DA, Rich JN, Friedman HS and Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265, 2006.
2. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL and Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051, 1994.
3. Zhang J, Stevens MF, Laughton CA, Madhusudan S and Bradshaw TD: Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78: 103-114, 2010.
4. Riemenschneider MJ, Hegi ME and Reifenberger G: MGMT promoter methylation in malignant gliomas. Target Oncol 5: 161-165, 2010.
5. Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003.
6. Brandes AA, Tosoni A, Cavallo G, et al: Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95: 1155-1160, 2006.
7. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
8. Kaplan E and Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
9. Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
10. Wick A, Felsberg J, Steinbach JP, et al: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25: 3357-3361, 2007